Analysts Set Repligen Corporation (NASDAQ:RGEN) Target Price at $166.15

Shares of Repligen Corporation (NASDAQ:RGEN) have been given a consensus recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $166.1538.

Several research analysts have recently weighed in on RGEN shares. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Wells Fargo & Company dropped their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Royal Bank Of Canada started coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. HC Wainwright lifted their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Finally, Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th.

Institutional Investors Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP boosted its stake in Repligen by 54.7% during the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock valued at $9,166,000 after buying an additional 27,500 shares during the period. Glenmede Trust Co. NA boosted its stake in Repligen by 10.3% during the first quarter. Glenmede Trust Co. NA now owns 8,268 shares of the biotechnology company’s stock valued at $974,000 after buying an additional 770 shares during the period. Summitry LLC boosted its stake in Repligen by 37.0% during the first quarter. Summitry LLC now owns 2,385 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 644 shares during the period. Segall Bryant & Hamill LLC boosted its stake in Repligen by 5.5% during the first quarter. Segall Bryant & Hamill LLC now owns 155,025 shares of the biotechnology company’s stock valued at $18,265,000 after buying an additional 8,045 shares during the period. Finally, Amundi boosted its stake in Repligen by 7.0% during the first quarter. Amundi now owns 44,959 shares of the biotechnology company’s stock valued at $5,297,000 after buying an additional 2,925 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $123.95 on Wednesday. The stock has a market cap of $6.99 billion, a PE ratio of 137.72, a price-to-earnings-growth ratio of 2.39 and a beta of 1.09. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock has a fifty day moving average of $117.94 and a 200-day moving average of $139.74.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the business earned $0.39 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts anticipate that Repligen will post 1.99 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.